Abstract
Receptor tyrosine kinases (RTKs) are transmembrane proteins that play a critical role in stimulating signal transduction cascades to influence cell proliferation, growth, and differentiation and they have also been shown to promote angiogenesis when they are up-regulated or mutated. For this reason, their dysfunction has been implicated in the development of human cancer. Over the past decade, much attention has been devoted to developing inhibitors and antibodies against several classes of RTKs, including vascular endothelial growth factor receptors (VEGFRs), epidermal growth factor receptors (EGFRs), and platelet-derived growth factor receptors (PDGFRs). More recently, interest in the fibroblast growth factor receptor (FGFR) class of RTKs as a drug target for the treatment of cancer has emerged. Signaling through FGFRs is critical for normal cellular function and their dysregulation has been linked to various malignancies such as breast and prostate cancer. This review will focus on the current state of both small molecules and antibodies as FGFR inhibitors to provide insight into their development and future potential as anti-cancer agents.
Keywords: Antibodies, ATP Binding Site, Cancer, Fibroblast Growth Factor Receptor, Indolinone, Pyrido[2, 3-d]pyrimidine, Small Molecules, Tyrosine Kinase Inhibitor.
Anti-Cancer Agents in Medicinal Chemistry
Title:Targeting the Fibroblast Growth Factor Receptors for the Treatment of Cancer
Volume: 13 Issue: 5
Author(s): Steven M. Lemieux and M. Kyle Hadden
Affiliation:
Keywords: Antibodies, ATP Binding Site, Cancer, Fibroblast Growth Factor Receptor, Indolinone, Pyrido[2, 3-d]pyrimidine, Small Molecules, Tyrosine Kinase Inhibitor.
Abstract: Receptor tyrosine kinases (RTKs) are transmembrane proteins that play a critical role in stimulating signal transduction cascades to influence cell proliferation, growth, and differentiation and they have also been shown to promote angiogenesis when they are up-regulated or mutated. For this reason, their dysfunction has been implicated in the development of human cancer. Over the past decade, much attention has been devoted to developing inhibitors and antibodies against several classes of RTKs, including vascular endothelial growth factor receptors (VEGFRs), epidermal growth factor receptors (EGFRs), and platelet-derived growth factor receptors (PDGFRs). More recently, interest in the fibroblast growth factor receptor (FGFR) class of RTKs as a drug target for the treatment of cancer has emerged. Signaling through FGFRs is critical for normal cellular function and their dysregulation has been linked to various malignancies such as breast and prostate cancer. This review will focus on the current state of both small molecules and antibodies as FGFR inhibitors to provide insight into their development and future potential as anti-cancer agents.
Export Options
About this article
Cite this article as:
Lemieux M. Steven and Hadden Kyle M., Targeting the Fibroblast Growth Factor Receptors for the Treatment of Cancer, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (5) . https://dx.doi.org/10.2174/18715206113139990080
DOI https://dx.doi.org/10.2174/18715206113139990080 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigallocatechin-3-gallate Increases RXRγ-mediated Pro-apoptotic and Anti-invasive Effects in Gastrointestinal Cancer Cell Lines
Current Cancer Drug Targets Atypical GTPases as Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Guaraná a Caffeine-Rich Food Increases Oxaliplatin Sensitivity of Colorectal HT-29 Cells by Apoptosis Pathway Modulation
Anti-Cancer Agents in Medicinal Chemistry Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders
CNS & Neurological Disorders - Drug Targets A Review on Mechanisms of Anti Tumor Activity of Chalcones
Anti-Cancer Agents in Medicinal Chemistry Regulation of Hypoxia-inducible Factor-1α and Vascular Endothelial Growth Factor Signaling by Plant Flavonoids
Mini-Reviews in Medicinal Chemistry Anticancer Effects of Garlic and Garlic-derived Compounds for Breast Cancer Control
Anti-Cancer Agents in Medicinal Chemistry From Body Art to Anticancer Activities: Perspectives on Medicinal Properties of Henna
Current Drug Targets Analytical Characterization of Label-Free Immunosensor Subsystems Based on Multi-Walled Carbon Nanotube Array-Modified Gold Interface
Combinatorial Chemistry & High Throughput Screening Strategies to Overcome Multi-Drug Resistance in Cancer Cells: the Contribution of siRNA and Nanotechnologies
Current Organic Chemistry TGF-β1 Signalling, Connecting Aberrant Inflammation and Colorectal Tumorigenesis
Current Pharmaceutical Design Tumor Protein p63/microRNA Network in Epithelial Cancer Cells
Current Genomics Clinical Utility of Microarrays: Current Status, Existing Challenges and Future Outlook
Current Genomics MEMS and Microfluidics for Diagnostics Devices
Current Pharmaceutical Biotechnology Hypoxic Radiosensitizers and Hypoxic Cytotoxins in Radiation Oncology
Current Medicinal Chemistry - Anti-Cancer Agents The Stem Cell Niche as a Pharmaceutical Target for Prevention of Skeletal Metastases
Anti-Cancer Agents in Medicinal Chemistry Pathophysiological Role of Hepatocyte Nuclear Factor 6 in Negative Regulation of Hepatic Apoptosis: A Novel Hypothesis
Current Molecular Medicine Multi-Nuclear Platinum Drugs: A New Paradigm in Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Computer-Aided Drug Design for AMP-Activated Protein Kinase Activators
Current Computer-Aided Drug Design